DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. ('TriSalus' or the 'Company') (Nasdaq: TLSI), a leader in oncology innovations integrating advanced delivery technology to transform treatment for liver and pancreatic tumors, today announced the launch of the TriNav® LV Infusion System and TriGuide™ Guiding Catheter.

丹佛--（商业新闻短讯）--TriSalus Life Sciences®Inc.（“TriSalus”或“公司”）（纳斯达克：TLSI）是肿瘤学创新的领导者，集成了先进的输送技术来改变肝脏和胰腺肿瘤的治疗方法，今天宣布推出TriNav®LV输注系统和TriGuide™引导导管。

These new devices are designed to optimize therapeutic delivery, enhancing treatment options and potentially improving outcomes for patients..

这些新设备旨在优化治疗效果，增强治疗选择，并可能改善患者的预后。。

Highlights of the Launch:

发布亮点：

Expanded Patient Access: The TriNav LV Infusion System is tailored for larger vessels (3.5-5.0 mm), increasing the number of patients eligible for TriSalus' proprietary Pressure-Enabled Drug Delivery (PEDD™) technology.

扩大患者访问范围：TriNav LV输液系统专为更大的血管（3.5-5.0 mm）量身定制，增加了符合TriSalus专有压力启用药物输送（PEDD™）技术的患者数量。

Comprehensive Device Portfolio: This launch marks an expansion of TriSalus’ PEDD device offerings, now covering vessel sizes from 1.5 mm to 5.0 mm, giving interventional radiologists a broader range of treatment options and increasing the Total Addressable Market (TAM).

全面的设备组合：此次发布标志着TriSalus PEDD设备产品的扩展，现在覆盖的血管尺寸从1.5毫米到5.0毫米，为介入放射科医生提供了更广泛的治疗选择，并增加了总可寻址市场（TAM）。

Innovative Design for Ease of Access: The new TriGuide Guiding Catheters, uniquely equipped with a larger inner diameter, lubricious inner lining, and reverse curve design, are the first of their kind to support femoral access for the TriNav LV Infusion System, enhancing procedural efficiency.

易于接近的创新设计：新型TriGuide引导导管独特地配备了更大的内径，有色内衬和反向曲线设计，是第一种支持TriNav LV输液系统股骨通路的导管，提高了手术效率。

High Satisfaction Among Early Users: In a limited market release, physicians reported a 97% satisfaction rate with the TriNav LV Infusion System, underscoring its clinical effectiveness and ease of use.

早期用户的满意度很高：在有限的市场发布中，医生报告TriNav LV输液系统的满意度为97%，强调了其临床有效性和易用性。

Reimbursement Compatibility: The TriNav LV Infusion System is eligible for the same HCPCS codes—C9797 for procedures and C1982 for devices—as the existing TriNav products, supporting seamless integration into current billing structures.

报销兼容性：TriNav LV输液系统符合与现有TriNav产品相同的HCPCS代码-程序为C9797，设备为C1982，支持无缝集成到当前的计费结构中。

'We are thrilled to introduce TriNav LV, an infusion system developed in direct response to customer feedback for a larger-diameter PEDD device suited for lobar therapeutic delivery in patients with larger vessels,' said Mary Szela, Chief Executive Officer and President of TriSalus. 'This launch is a testament to our commitment to meeting clinician needs and marks the first of several innovative products we plan to introduce over the next 12 to 18 months.

TriSalus首席执行官兼总裁玛丽·斯泽拉（MarySzela）说：“我们很高兴推出TriNav LV，这是一种直接响应客户反馈而开发的输液系统，用于更大直径的PEDD设备，适用于大血管患者的肺叶治疗。”此次发布证明了我们对满足临床医生需求的承诺，也是我们计划在未来12至18个月推出的几款创新产品中的第一款。

Our focus remains on advancing our pipeline to make a significant difference in patient outcomes and to drive progress in cancer treatment.'.

我们的重点仍然是推进我们的管道，以显着改善患者预后并推动癌症治疗的进展。”。

About TriSalus Life Sciences

关于TriSalus Life Sciences

TriSalus Life Sciences® is an oncology focused medical technology business providing disruptive drug delivery technology with the goal of improving therapeutics delivery to liver and pancreatic tumors.

TriSalus Life Sciences®是一家专注于肿瘤学的医疗技术业务，提供破坏性药物输送技术，旨在改善肝脏和胰腺肿瘤的治疗效果。

The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD™) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors.

该公司的平台包括利用专有药物输送技术和临床阶段研究性免疫疗法的设备。该公司的两个FDA批准的设备使用其专有的压力启用药物输送™（PEDD™）方法来提供一系列治疗方法：用于肝肿瘤肝动脉输注的TriNav®输注系统和用于胰腺肿瘤的胰腺逆行静脉输注系统。

PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes.

PEDD是一种新型的递送方法，旨在解决胰腺动脉灌注的解剖学限制。PEDD方法以对肿瘤提供更多治疗的方式调节压力和流量，并旨在减少对正常组织的不希望的输送，从而有可能改善患者的预后。

Nelitolimod, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects within the liver and systemically.

Nelitolimod是该公司的研究性免疫治疗候选药物，旨在通过治疗许多肿瘤产生的免疫抑制环境来改善患者的预后，这可能使目前的免疫疗法对肝脏和胰腺无效。在压力激活的区域免疫肿瘤学™（PERIO）临床试验期间产生的患者数据支持以下假设：通过PEDD递送的奈利莫德可能在肝脏和全身内具有良好的免疫作用。

The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by the PEDD method are commonly present as well. Nelitolimod delivered by the PEDD method will be studied across several indications in an effort to address immune dysfunction and overcome drug delivery barriers in the liver and pancreas..

奈利托莫德的靶标TLR9在各种癌症类型中表达，并且通常也存在PEDD方法解决的机械障碍。通过PEDD方法递送的奈利托莫德将在多个适应症中进行研究，以解决免疫功能障碍并克服肝脏和胰腺中的药物递送障碍。。

In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at trisaluslifesci.com and follow us on X (formerly Twitter) and LinkedIn..

通过与全国领先的癌症中心合作，并利用深入的免疫肿瘤学专业知识和创新技术开发，TriSalus致力于推进创新，改善患者的预后。在trisaluslifesci.com了解更多信息，并在X（以前的Twitter）和LinkedIn上关注我们。。